613675-51-7

Upstream product

• 6213-94-1 trimethylsiloxyethene 
• 105-07-7 4-cyanobenzaldehyde 
• 1097210-67-7 3-(4-cyanophenyl)-3-hydroxypropanoic acid 
• 1126-27-8 1-cyclopropyl-4-benzonitrile 

Downstream Products

• 1097210-68-8 C₁₆H₂₅NO₂Si 

Relevant academic research and scientific papers

Lithium acetate-catalyzed crossed aldol reaction between aldehydes and trimethylsilyl enolates generated from other aldehydes

Crossed aldol reaction between aromatic aldehydes having an electron-withdrawing group and trimethylsilyl enolates generated from several aldehydes proceeded smoothly in dry or water-containing DMF in the presence of a catalytic amount of a Lewis base such as lithium acetate or lithium benzoate. Successive reduction of the produced aldehydes with sodium borohydride (NaBH4) afforded the corresponding 1,3-diols in good to high yields in one-pot. Copyright

Catalytic 1,3-Difunctionalization via Oxidative C-C Bond Activation

Electronegative substituents arrayed in 1,3-relationships along saturated carbon frameworks can exert strong influence over molecular conformation due to dipole minimization effects. Simple and general methods for incorporation of such functional group relationships could thus provide a valuable tool for modulating molecular shape. Here, we describe a general strategy for the 1,3-oxidation of cyclopropanes using aryl iodine(I-III) catalysis, with emphasis on 1,3-difluorination reactions. These reactions make use of practical, commercially available reagents and can engage a variety of substituted cyclopropane substrates. Analysis of crystal and solution structures of several of the products reveal the consistent effect of 1,3-difluorides in dictating molecular conformation. The generality of the 1,3-oxidation strategy is demonstrated through the catalytic oxidative ring-opening of cyclopropanes for the synthesis of 1,3-fluoroacetoxylated products, 1,3-diols, 1,3-amino alcohols, and 1,3-diamines.

SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS

Compounds of Formula (I) or pharmaceutically acceptable salts, solvates, or esters thereof, are useful in treating diseases or conditions mediated by CB1receptors, such as metabolic syndrome and obesity, neuroinflammatory disorders, cognitive disorders and psychosis, addiction (e.g., smoking cessation), gastrointestinal disorders, and cardiovascular conditions.